THC Tenet Healthcare Corporation

This article from MSN (Microsoft Network) is about Tenet Healthcare Corporation (THC) and its earnings momentum. It highlights that ambulatory care is a key factor driving strong financial performance for the company. The specific details of the earnings and ambulatory care's contribution are expected to be elaborated within the full article.

Swedbank AB significantly increased its stake in Tenet Healthcare Corporation (NYSE:THC) during the third quarter, boosting its holdings by 95.6% to 127,383 shares worth $25.86 million. This comes as Tenet Healthcare reported strong Q3 earnings, beating analyst estimates and issuing optimistic FY2025 guidance. The stock currently holds a "Moderate Buy" consensus rating from analysts, with insider selling also noted in recent transactions.

Tenet Healthcare Corporation (THC) is experiencing strong earnings momentum, particularly driven by its ambulatory care segment. The company's Q3 2025 results showed a significant increase in adjusted EBITDA, and analysts have maintained positive ratings and price targets due to robust operational execution and growth in outpatient procedures. Tenet also raised its 2025 adjusted EBITDA guidance, reflecting continued profitability and effective cost management.

Voya Investment Management LLC reduced its stake in Tenet Healthcare Corporation by 17.2% in Q3, now holding 106,266 shares valued at $21.58 million. Despite high institutional ownership (95.44%), insiders have been net sellers, offloading 45,500 shares worth $9.25 million. Tenet Healthcare reported strong Q3 earnings, beating expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $231.81.

Wedge Capital Management L L P NC reduced its stake in Tenet Healthcare Corporation (NYSE: THC) by 14.8% during the third quarter, selling 33,748 shares and owning 193,864 shares valued at $39.36 million. Tenet Healthcare recently beat Q3 earnings estimates, reporting $3.70 EPS against an estimated $3.33, and provided strong FY2025 guidance. The stock currently holds a "Moderate Buy" analyst rating with an average target price of $231.81.

Tenet Healthcare (THC) is under investor scrutiny due to strong earnings and a potentially undervalued stock, despite policy debates regarding the Affordable Care Act and a Cigna contract dispute. While its current P/E ratio of 12.7x is significantly lower than industry averages, suggesting undervaluation, a discounted cash flow model indicates an even deeper value, with a fair value of around $370.12. However, these positive valuations are tempered by risks associated with potential changes to ACA subsidies and the outcome of the Cigna dispute.